Результати пошуку - David M. Pariser

Уточнити результати
  1. 1
    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice

    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice за авторством David M. Pariser, Terri L. Meinking, Margie Bell, William G. Ryan

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis

    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis за авторством Richard K. Scher, Phoebe Rich, Boni E. Elewski, David M. Pariser

    Опубліковано 2013
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing

    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing за авторством Richard Nuccitelli, Pamela Nuccitelli, Changyi Li, Suman Narsing, David M. Pariser, Kaying Lui

    Опубліковано 2011
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis за авторством David M. Pariser, Brad Schenkel, Chureen Carter, Kamyar Farahi, T. Michelle Brown, Charles N. Ellis

    Опубліковано 2015
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States за авторством Alexa B. Kimball, Jennifer Schenfeld, Neil A. Accortt, Mary S. Anthony, Kenneth J. Rothman, David M. Pariser

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris

    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris за авторством Warren W. Piette, Susan C. Taylor, David M. Pariser, Michael Jarratt, Pranav Sheth, David J. Wilson

    Опубліковано 2008
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety... за авторством Robert Bissonnette, David M. Pariser, Norman Wasel, Joana Gonçalves, Robert M. Day, Rongdean Chen, Michael Sebastian

    Опубліковано 2016
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up

    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follo... за авторством Eduardo Tschen, David S.Y. Wong, David M. Pariser, F E DUNLAP, Anna Houlihan, Mary Beth Ferdon

    Опубліковано 2006
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patient... за авторством Kim Papp, David M. Pariser, Mary Catlin, G. Wierz, Greg Ball, B. Akinlade, Bernhardt Zeiher, James G. Krueger

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis за авторством Amy S. Paller, Elaine C. Siegfried, David M. Pariser, Kara Rice, Mona Trivedi, Jan Iles, David H. Collier, Greg Kricorian, Richard Langley

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials за авторством Linda Stein Gold, Mark Lebwohl, Jeremy Sugarman, David M. Pariser, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert J. Israel, Tage Ramakrishna

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials за авторством Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William Philip Werschler, Lawrence Green, Richard D. Mamelok, Janice Drew, John Quiring, David M. Pariser

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial за авторством Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis за авторством Amy S. Paller, Elaine C. Siegfried, Richard Langley, Alice B. Gottlieb, David M. Pariser, Ian Landells, Adelaide A. Hebert, Lawrence F. Eichenfield, Vaishali Patel, Kara Creamer, Angelika Jahreis

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies за авторством Mark Boguniewicz, Andrew Alexis, Lisa A. Beck, Julie Block, Lawrence F. Eichenfield, Luz Fonacier, Emma Guttman‐Yassky, Amy S. Paller, David M. Pariser, Jonathan I. Silverberg, Mark Lebwohl

    Опубліковано 2017
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  16. 16
    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis за авторством Eric L. Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, T. Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David M. Pariser

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis за авторством Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, Naji Tawfik, Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser

    Опубліковано 2003
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)

    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) за авторством David M. Pariser, Eric L. Simpson, Abhijit Gadkari, Thomas Bieber, David J. Margolis, T. Michelle Brown, Lauren Nelson, Puneet Mahajan, Matthew Reaney, Isabelle Guillemin, Usha G. Mallya, Laurent Eckert

    Опубліковано 2019
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the op... за авторством Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results за авторством Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: